跳至主要内容
临床试验/CTRI/2024/06/068564
CTRI/2024/06/068564尚未招募4 期

Efficacy and safety of daily versus alternate day add-on therapy with teneligliptin in type 2 diabetes mellitus patients: An open label, parallel group, randomized controlled study. - NI

ONE0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
ONE

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Patients with T2DM visiting Medicine / Endocrinology OPD/Ward who are taking metformin =1000 mg for a duration of 3 months or more.
  • 2) Age:18- 59 years.
  • 3) HbA1c 7-9 %

排除标准

  • 1) Type 1 Diabetes patients.
  • 2) Patients taking metformin for less than 3 months duration.
  • 3) Patients with known allergy to study drugs.
  • 4) Pregnant and lactating women.
  • 5)Patients with uncontrolled cardiovascular disorders.
  • 6) Patients with severe life-threatening diseases.
  • 7) Patients having renal dysfunction (serum creatinine 1.5 times more than the upper normal limit range).
  • 8) Cases with hepatic dysfunction (SGOT and/ or SGPT levels 3-fold more than upper limit range).
  • 9) Patients who have recent history of diabetic ketoacidosis.
  • 10) Patients who are not willing / unable to give written informed consent.

研究者

发起方
ONE

相似试验